IP Library › Granted Patent US 8,183,243
Granted Patent B2
US 8,183,243 · App. 13/158,920 · Granted May 22, 2012

Melanocortin receptor agonists

Assignee: LG Life Sciences Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,183,243
App. No.
13/158,920
Granted
May 22, 2012
Kind
B2
Abstract

The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.

Claims (1)

1. (2S)-N-{(3S,5S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-yl]carbonyl}-5-[(4-methylpiperazin-1-yl)carbonyl]pyrrolidin-3-yl}-N-(4,4-dimethylcyclohexyl)tetrahydrofuran-2-carboxamide or a salt thereof.

Assignments (1)
MERGER Recorded Sep 2, 2017
From: LG LIFE SCIENCES LTD.
To: LG CHEM, LTD.
Reel/Frame 043475/0619 →
Priority Claims (1)
KR 10-2008-0112403 · Nov 12, 2008 · national
Continuity (2)
Division 12615407 · Nov 10, 2009
Related Publication 20110245500A1 · Oct 6, 2011